Sphera Funds Management LTD. purchased a new stake in shares of SAGE Therapeutics Inc (NASDAQ:SAGE) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor purchased 60,000 shares of the biopharmaceutical company’s stock, valued at approximately $8,475,000. SAGE Therapeutics comprises about 1.0% of Sphera Funds Management LTD.’s investment portfolio, making the stock its 23rd largest holding. Sphera Funds Management LTD. owned about 0.13% of SAGE Therapeutics as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. FMR LLC boosted its position in SAGE Therapeutics by 0.3% in the 3rd quarter. FMR LLC now owns 6,999,644 shares of the biopharmaceutical company’s stock valued at $988,700,000 after buying an additional 22,266 shares during the period. BlackRock Inc. boosted its position in SAGE Therapeutics by 0.9% in the 3rd quarter. BlackRock Inc. now owns 2,816,410 shares of the biopharmaceutical company’s stock valued at $397,818,000 after buying an additional 23,862 shares during the period. OppenheimerFunds Inc. boosted its position in SAGE Therapeutics by 2.2% in the 2nd quarter. OppenheimerFunds Inc. now owns 1,598,167 shares of the biopharmaceutical company’s stock valued at $250,162,000 after buying an additional 34,389 shares during the period. Bank of New York Mellon Corp boosted its position in SAGE Therapeutics by 7.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,564,548 shares of the biopharmaceutical company’s stock valued at $244,898,000 after buying an additional 110,134 shares during the period. Finally, BB Biotech AG boosted its position in SAGE Therapeutics by 6.9% in the 2nd quarter. BB Biotech AG now owns 1,071,373 shares of the biopharmaceutical company’s stock valued at $167,702,000 after buying an additional 68,934 shares during the period.
Several research firms have issued reports on SAGE. BidaskClub raised shares of SAGE Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Tuesday. Oppenheimer set a $170.00 price objective on shares of SAGE Therapeutics and gave the company a “buy” rating in a research report on Tuesday, November 20th. Leerink Swann began coverage on shares of SAGE Therapeutics in a research report on Monday, November 12th. They issued an “underperform” rating and a $80.00 price objective for the company. JPMorgan Chase & Co. set a $205.00 price objective on shares of SAGE Therapeutics and gave the company a “buy” rating in a research report on Tuesday, November 6th. Finally, Royal Bank of Canada boosted their price objective on shares of SAGE Therapeutics from $259.00 to $261.00 and gave the company an “outperform” rating in a research report on Monday, November 5th. Two analysts have rated the stock with a sell rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. SAGE Therapeutics currently has a consensus rating of “Buy” and an average price target of $204.14.
Shares of SAGE traded up $0.92 during mid-day trading on Friday, hitting $106.80. The company’s stock had a trading volume of 19,466 shares, compared to its average volume of 351,633. SAGE Therapeutics Inc has a 52-week low of $100.75 and a 52-week high of $195.97. The stock has a market capitalization of $5.09 billion, a PE ratio of -15.06 and a beta of 2.72.
SAGE Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($2.63) earnings per share for the quarter, missing the consensus estimate of ($2.41) by ($0.22). During the same period in the previous year, the firm earned ($1.97) EPS. On average, equities analysts expect that SAGE Therapeutics Inc will post -7.58 earnings per share for the current fiscal year.
WARNING: This article was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/12/07/60000-shares-in-sage-therapeutics-inc-sage-acquired-by-sphera-funds-management-ltd.html.
SAGE Therapeutics Company Profile
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).
Featured Story: Short Selling – Explanation For Shorting Stocks
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.